Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31370383 | 0.88 | KDM4E (0.43) | KDM4EGPBAR1ALDH1A1SMN1; SMN2PDE4A | |
| SCHEMBL27315841 | 0.88 | KDM4E (0.43) | KDM4EGPBAR1ALDH1A1SMN1; SMN2PDE4A | |
| SCHEMBL25950269 | 0.88 | KDM4E (0.43) | KDM4EGPBAR1ALDH1A1SMN1; SMN2PDE4A | |
| SCHEMBL27448156 | 0.86 | KDM4E (0.41) | KDM4EGPBAR1ALDH1A1SMN1; SMN2PDE4A | |
| SCHEMBL27443608 | 0.86 | KDM4E (0.41) | KDM4EGPBAR1ALDH1A1SMN1; SMN2PDE4A | |
| SCHEMBL20224631 | 0.86 | KDM4E (0.38) | KDM4EGPBAR1ALDH1A1PDE4ALMNA | |
| SCHEMBL27104562 | 0.85 | KDM4E (0.37) | KDM4EGPBAR1ALDH1A1PDE4A | |
| SCHEMBL20224390 | 0.85 | KDM4E (0.37) | KDM4EGPBAR1ALDH1A1PDE4A | |
| SCHEMBL29300253 | 0.83 | NMT2 (0.35) | KDM4EGPBAR1ALDH1A1 | |
| SCHEMBL25951399 | 0.83 | BMP1 (0.36) | KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | CD2BP2, DNPEP, LNPEP | KDM4E 2843/4885GPBAR1 1867/4885ALDH1A1 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.